Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting an observational study titled CIBINQO™ Pregnancy Registry: An Observational Study of the Safety of Abrocitinib Exposure in Pregnant Women and Their Offspring. The study aims to assess the safety of the drug Abrocitinib, marketed as CIBINQO, in pregnant women and their children. This research is significant as it seeks to provide insights into the drug’s safety profile during pregnancy, a critical concern for healthcare providers and patients.
The intervention being tested is Abrocitinib, a drug taken orally, intended to treat moderate-to-severe atopic dermatitis. The study compares pregnant women exposed to Abrocitinib with those who are not, to evaluate any potential risks associated with the drug during pregnancy.
This is an observational cohort study with a prospective time perspective. Participants will receive standard care, and data will be collected at specific intervals: enrollment, end of the second trimester, and pregnancy outcome. For live births, data will also be collected when the child is 4 and 12 months old.
The study began on July 25, 2023, and is currently recruiting participants. The last update was submitted on July 7, 2025. These dates are crucial as they indicate the study’s progress and timeline for data collection and analysis.
The outcome of this study could impact Pfizer’s stock performance, as positive safety results might enhance investor confidence and market position. Given the competitive landscape in the pharmaceutical industry, particularly in dermatology treatments, this study’s findings could also influence Pfizer’s standing relative to its competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.